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Abstract
Objective: We established the Leipzig (LIFE) Heart Study, a biobank and database of patients with different stages of
coronary artery disease (CAD) for studies of clinical, metabolic, cellular and genetic factors of cardiovascular diseases.
Design: The Leipzig (LIFE) Heart Study (NCT00497887) is an ongoing observational angiographic study including subjects
with different entities of CAD. Cohort 1, patients undergoing first-time diagnostic coronary angiography due to suspected
stable CAD with previously untreated coronary arteries. Cohort 2, patients with acute myocardial infarction (MI) requiring
percutaneous revascularization. Cohort 3, patients with known left main coronary artery disease (LMCAD).
Results: We present preliminary results of demographics and phenotyping based on a 4-years analysis of a total of 3,165
subjects. Cohort 1 (n=2,274) shows the typical distribution of elective coronary angiography cohorts with 43% cases with
obstructive CAD and 37% normal angiograms. Cohorts 2 and 3 consist of 590 and 301 subjects, respectively, adding patients
with severe forms of CAD. The suitability of the database and biobank to perform association studies was confirmed by
replication of the CAD susceptibility locus on chromosome 9p21 (OR per allele: 1.55 (any CAD), 1.54 (MI), 1.74 (LMCAD),
p,10
26, respectively). A novel finding was that patients with LMCAD had a stronger association with 9p21 than patients
with obstructive CAD without LMCAD (OR 1.22, p=0.042). In contrast, 9p21 did not associate with myocardial infarction in
excess of stable CAD.
Conclusion: The Leipzig (LIFE) Heart Study provides a basis to identify molecular targets related to atherogenesis and
associated metabolic disorders. The study may contribute to an improvement of individual prediction, prevention, and
treatment of CAD.
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Introduction
Coronary artery disease (CAD) and its complications such as
myocardial infarction and congestive heart failure are projected to
remain the leading cause of mortality in the world [1]. CAD is
caused by a complex pattern of interaction of genetic factors and
life-style. However, individual CAD susceptibility is not well
understood. Combined assessment of traditional risk factors, clinical
phenotypes, genetic information as well as proteomic and metabolic
data is a promising strategy for the assessment of the individual
cardiovascular risk – the premise of ‘personalized medicine’ [2].
A significant source of limitation in many previous genetic
studies of CAD has been from imprecise phenotypic character-
ization of cases and controls [3,4]. Coronary lesions show a wide
range of clinical manifestations, from asymptomatic to stable
symptomatic disease with stress-induced angina to the point of
acute coronary syndrome, myocardial infarction and even cardiac
death. This contributes substantially to the heterogeneity of
cohorts that have been assessed to date and many of them are a
medley of subjects with stable angina, acute coronary syndrome
and with a history of myocardial infarction or coronary
revascularization. A detailed and highly standardized phenotypic
characterization might therefore contribute to a more valid
classification of cases and controls. Moreover, a precise assessment
of confounders such as life-style factors and concomitant disease
might allow for a more appropriate adjustment for these
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novel biomarkers using e.g. transcriptomic, proteomic or metabo-
lomic analysis [5,6].
The Leipzig (LIFE) Heart Study represents a biobank and data
base with detailed cardiovascular, metabolic and biochemical
characterization of patients with different entities of atherosclerotic
coronary disease. These include subjects undergoing first-time
coronary angiography due to suspected CAD but previously
unknown coronary status (cohort 1), subjects with acute myocar-
dial infarction as first manifestation of CAD (cohort 2) and subjects
with left main coronary artery disease (cohort 3). The suitability of
the database and biobank to perform association analyses will be
supported by assessing the CAD susceptibility locus on chromo-
some 9p21.
Methods
A detailed description of methods is provided in the online
supplement (Data S1).
Overview
The Leipzig (LIFE) Heart Study is designed as observational
study to evaluate biochemical and molecular biomarkers and their
ability to assess the presence and severity of CAD in symptomatic
subjects (cross-sectional) and to predict the future course of disease
(longitudinal). Follow-up at 5-year intervals will provide prospec-
tive information about major cardiac clinical events of the initial
study subjects (cardiovascular death, myocardial infarction/re-
infarction, coronary revascularization). The study meets the
ethical standards of the Declaration of Helsinki. It has been
approved by the Ethics Committee of the Medical Faculty of the
University Leipzig, Germany (Reg. No 276-2005) and is registered
with ClinicalTrials.gov (NCT00497887). Written informed con-
sent has been obtained from all participants involved in the study.
Study cohorts
Cohort 1: Subjects with suspected CAD. Patients included in
cohort 1 are referred to coronary angiography by an outpatient
cardiologist. Coronary angiography was indicated by clinical
symptoms and non-invasive testing. Patients with any previous
coronary revascularization in form of percutaneous coronary
intervention (PCI) or coronary artery bypass graft (CABG) are
excluded to obtain subjects with coronary first-time events and
untreated coronary arteries (Table 1).
Cohort 2: Subjects with myocardial infarction. Patients included
in cohort 2 required primary or rescue PCI caused by acute
myocardial infarction. Symptom onset and interval to revascular-
ization is limited to a maximum of 60 and 36 hours before
enrollment and blood taking, respectively. The rationale is to
evaluate circulating biomarkers of the early postinfarction phase
and their ability to predict the clinical outcome and risk for future
coronary events (Table 1).
Cohort 3: Subjects with left main coronary artery disease
(LMCAD). Patients included in cohort 3 have known CAD and
significant LMCAD with luminal reduction $50% ostial, mid-
shaft or at bifurcation. Subjects may be treated conservative or had
required revascularization in history (Table 1).
Data collection
Data collection in the Leipzig (LIFE) Heart Study reverts to
standardized, validated instruments and procedures which have
been proved of value in epidemiologic and clinical studies.
Medical and family history, life style habits and medication are
surveyed in a standardized interview. Subjects with suspected
CAD pass an extended standardized study program including
anthropometric measurements, blood pressure measurement,
electrocardiogram, exercise test, echocardiography (Figure S1,
Table S1) and ultrasound of carotid (Figure S2) and peripheral
arteries besides coronary angiography. Therefore, atherosclerotic
burden is estimated in the three mostly affected arterial beds:
peripheral, carotid and coronary arteries. Coronary angiography
is performed following the standards of the institution. Gensini
score index is calculated and patients are classified in sets of
subjects with normal angiogram (no CAD), subjects with wall
irregularities but ,50% luminal reduction (CAD,50%) and
subjects with obstructive CAD defined as at least one stenosis of
50% or more in any coronary vessel (CAD$50%) (Figure S3).
Significant LMCAD was defined as visual luminal reduction
$50% of the left main trunk (Figure S4).
Laboratory
Blood of subjects with suspected CAD (cohort 1) is drawn before
invasive diagnostic, hence unaffected by revascularization proce-
dures and escalation of pharmacological therapy. Blood of subjects
with acute myocardial infarction (cohort 2) is drawn within 6 to
36 hours after the interventional revascularization. Blood of
patients with LMCAD (cohort 3) is drawn irrespective of earlier
coronary procedures. Multiple aliquots of serum, plasma, whole
blood, DNA, RNA and peripheral mononuclear blood cells are
stored at 280uC or liquid nitrogen for further analysis. Clinical
chemistry and a set of metabolic, cardiac and inflammatory
marker are measured on the day of blood sampling using an
Table 1. Inclusion and exclusion criteria of the Leipzig (LIFE) Heart Study.
Inclusion criteria Exclusion criteria
Overall Age 18–85 years Severe systemic diseases (e.g. active cancer, autoimmune
disease)
Ability to consent
Cohort 1 Patients with suspected CAD referred for diagnostic invasive coronary angiography Coronary revascularization (PCI/CABG) in history
Acute coronary syndrome
Severe valvular disease
Cohort 2 Patients with acute myocardial infarction (Troponin T.0.04 and angiographic
detectable culprit lesion)
Coronary revascularization (PCI/CABG) prior to current
myocardial infarction
Cohort 3 Patients with angiographic $50% luminal reduction of the left main coronary artery
PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft.
doi:10.1371/journal.pone.0029070.t001
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Mannheim, Germany). Single nucleotide polymorphisms (SNP)
rs10757274, rs2383206, rs2383207 and rs10757278 are genotyped
for replication studies of the CAD-susceptibility locus on chr9p21.
Statistics
The sample size calculation to estimate the suitability of our
study for genetic studies is given in the Table S2. SPSS version
16.0 was used for statistical analyses. Categorical data are
expressed as numbers and percentages and were compared using
the x
2 or Fisher’s exact test, as appropriate. Continuous variables
are expressed as the arithmetic mean 6 standard deviation for
normally distributed variables and as geometric mean 6 standard
deviation for non-normally distributed variables. They were
compared using a one-way ANOVA and Kruskal-Wallis test with
post-hoc test, respectively. P-values,0.05 were considered statis-
tically significant. Genetic association analyses were performed
using logistic regression techniques. Associations of cardiologic
endpoints with single SNPs and the GGGG haplotype were
adjusted for age, sex, diabetes and cigarette smoking packyears.
CAD phenotypes (except myocardial infarction) were also adjusted
for HDL and LDL. Additive models were calculated throughout.
Calculations were performed using the statistical software package
R (www.r-project.org).
Results
Description of study cohorts
Recruitment of subjects started in December 2006 and is
ongoing. The current results are based on 3.165 subjects in 3
cohorts with different entities of CAD (Table 2).
Cohort 1: Suspected coronary artery disease
Cohort 1 consists of 1,457 men and 817 women, who were
referred for diagnostic coronary angiography due to suspected
coronary artery disease. Completeness of phenotyping was high
for blood sampling, laboratory analyses, interview and ECG
(100%, respectively), echocardiography (99%), carotid ultrasound
(96%) and ABI (95%). An exercise stress test was completed in
56% of the study participants while remaining patients had
cardiologic or orthopedic disabilities. Coronary angiography was
performed in 97% of study patients (indication for coronary
angiography was revised in n=100 subjects after study enroll-
ment). Angiographically detectable atherosclerosis was present in
the coronary tree of 71% of men and 48% of women. The
remaining subjects were free of angiographically visible CAD.
49% of males and 29% of females had luminal reduction of $50%
in at least one major coronary artery, resulting in assignment to
percutaneous coronary intervention or coronary artery bypass
grafting in 38% of males and 22% of females. 32% of men and
18% of women had a multi-vessel disease. Gensini scores of the
male and female subsets with CAD$50% were 40632 and
32628, respectively. Distributions of angiographic findings are
shown in Figure 1 as age strata in 10-years intervals. All age strata
comprise subjects with various stages of CAD as well as subjects
with angiographically normal coronary arteries.
Cohort 2: Acute myocardial infarction
Cohort 2 consists of 431 men and 159 women with acute
myocardial infarction, which were included 6 to 36 hours after
PCI. The mean time from PCI to inclusion was 2068 hours. 70%
had an ST-elevation myocardial infarction (CK 36634 U/l) and
remaining patients occurred with non-ST-elevation myocardial
infarction (CK 15614 U/l). Myocardial infarction resulted in a
reduction of left ventricular ejection fraction ,50% in 48% of
STEMI cases and 34% of NSTEMI cases. All subjects with
myocardial infarction had an identifiable culprit lesion, in 34% it
was localized in the right coronary artery, 48% in the left anterior
descending, and 18% in the circumflex or affiliated branches. 52%
had a single-vessel-disease while 48% had a multi-vessel disease yet
with further significant stenosis besides the culprit lesion. Gensini
scores were 40629 in NSTEMI cases and 45628 in STEMI
cases.
Cohort 3: Left main coronary artery disease
Cohort 3 consists of 242 men and 59 women with known left
main coronary artery disease ($50% stenosis). Patients were
recruited at an average of 6 years after diagnosis (range 0–37
years). Therefore, most of these individuals had already undergone
coronary revascularization by PCI (35% ), bypass graft (30%) or
both (19%). Average age at first diagnosis of CAD was 63611
years. Interestingly, 46% of these patients reported a myocardial
infarction in their recollected history. According to retrospective
angiograms mean value of luminal stenosis was 70617% (range
50–100%).
Demographic and cardiovascular risk factors
Demographic and clinical characteristics of study subjects are
summarized for each cohort and for men and women, separately
(Table 3 and 4). As expected from the earlier onset of CAD, men
included in the study were significantly younger than women
(62.0611.6 and 64.7611.2 years, respectively). Study participants
were obese with mean body-mass index .28 kg/m
2 in all three
cohorts. One third of study subjects were categorized as diabetic in
both genders. In cohort 1, 21% of men and 11% of women were
current smoker and 52% and 16% had a history of smoking,
Table 2. Numbers of subjects recruited in several cohorts and
composite phenotypes.
Cohort/Coronary phenotype N (%)
All 3165 (100)
Cohort 1 (suspected CAD, total) 2274 (72)
- normal angiogram 812 (26)
- non-obstructive CAD
a 456 (15)
- obstructive CAD
b 906 (28)
- no angiography 100 (3)
Cohort 2 (myocardial infarction) 590 (19)
Cohort 3 (LMCA disease) 301 (9)
All CAD (obstructive from Cohorts 1, 2, 3) 1797 (57)
Stable CAD (obstructive from Cohorts 1, 3)
c 956 (30)
Single-vessel-disease (obstructive from Cohorts 1, 2) 635 (20)
Multi-vessel-disease (obstructive from Cohorts 1, 2, 3) 1162 (37)
All myocardial infarction (cohort 1, 2, 3)
d 841 (27)
All LMCA disease (from Cohorts 1, 2, 3) 492 (16)
asubjects with angiographic coronary wall irregularities ,50% luminal
reduction.
bsubjects with angiographic stenoses $50% luminal reduction in at least one
major coronary artery.
csubjects of cohort 1 and 3 with normal troponin level, obstructive CAD and no
myocardial infarction in their recollected history.
dsubjects of cohort 1 and 2 with elevated troponin and angiographically culprit
coronary lesion, subjects of cohort 3 with myocardial infarction in their
recollected history.
doi:10.1371/journal.pone.0029070.t002
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much higher (49% and 36% of men and women, respectively).
Comparison of subjects with angiographically normal and
diseased coronary arteries showed an expected distribution of
traditional risk factors for both genders. CAD-patients were older,
smoked more, were more often diabetic, had lower levels of HDL,
higher levels of LDL and higher levels of C-reactive protein
(Table 3 and 4). Interestingly, the majority of subjects in cohort 1
were already treated with acetylsalicylic acid (52%), renin
angiotensin aldosteron system inhibitors (69%), betablocker
(58%), Calcium antagonists (24%), diuretics (39%) and statins
(35%) before invasive coronary diagnostics.
Replication study of CAD susceptibility locus on
Chromosome 9p21
To assess the suitability for performing genetic association
studies, we finally tested for an association of CAD severity with
the chromosome 9p21 genotype. The latter had been identified as
the most robust locus associated with coronary artery disease and
myocardial infarction in recent genome-wide association studies
[7–10]. Replication of the chromosome 9p21 locus has been
suggested as quality control for further genetic studies of
cardiovascular disease [11]. We genotyped SNPs rs10757274,
rs2383206, rs2383207 and rs10757278 of the CAD-risk haplotypic
block on chromosome 9p21 (call rates 99%, 97%, 99% and 98%,
respectively). The risk allele (G) frequencies were 50%, 52%, 53%
and 49%, respectively, and were in strong linkage disequilibrium
(minimum of pairwise R
2=0.83, Figure S5). G-alleles of all four
SNPs were associated with obstructive CAD, myocardial infarc-
tion and LMCAD when comparing diseased subjects to those with
normal angiograms (Figure 2). The odds ratios of the risk-
haplotype were between 1.54 to 1.74 per allele (p-values 7.1610
28
to 6.9610
27) for all these forms of CAD using a logistic regression
analysis under the assumption of an additive model and after
adjustment for the traditional risk factors (Table 5). To assess the
effect of the 9p21 locus between different forms of CAD, we next
performed associations within CAD cohorts. Comparing subjects
with stable obstructive CAD to subjects with myocardial
infarction, no association with 9p21 variants was seen (OR 1.00,
CI 0.87–1.15). In contrast, patients with severe forms of CAD such
as LMCAD had a stronger association with 9p21 than patients
with obstructive CAD without LMCAD (OR 1.22, CI 1.01–1.48),
even though it must be noted that these results were at the margin
of statistical significance (p=0.042; Figure 2, Table 6).
Discussion
Here, we present the study design and data of 3.165 subjects
enrolled in the ongoing Leipzig (LIFE) Heart Study. The study
includes subjects with different severity and courses of coronary
artery disease. CAD was prevalent in 78% of males and 57% of
females, while the remaining subjects were free of angiographically
detectable CAD. Patients with obstructive CAD had the expected
higher level of conventional risk factors and confirmation of the
chromosome 9p21 risk locus indicates excellent power for genetic
association studies. Moreover, different entities of CAD included
in the study allowed detailed analyses within CAD populations.
Cohort 1 of the Leipzig (LIFE) Heart Study presents a typical
cohort of patients undergoing elective coronary angiography for
suspected CAD. In this cohort, 43% of individuals had obstructive
CAD while 37% were free of angiographically visible CAD. These
data are comparable with the NCDR CathPCI Registry of
397.954 individuals [12], where 38% had obstructive CAD and
39% no CAD (Figure 1). The selection of cases and controls in
genetic studies of CAD is a matter of ongoing discussion. Recent
Figure 1. Angiographic findings of subjects with suspected CAD (cohort 1). Arrangement in age strata beginning with 18–45 years followed
by 10-years intervals for men and women, separately. Coronary angiograms were interpreted as no CAD when angiographically normal coronary
arteries were found, the presence of wall irregularities (WI) was interpreted as intermediate coronary atherosclerosis (CAD,50%). Stenoses with
$50% luminal reduction were rated as obstructive CAD and assessed as 1-, 2- or 3-vessel disease (1VD, 2VD, 3VD). For comparison, representative
results of the American College of Cardiology National Data Registry (NCDR CathPCI Reg.) are shown including patients with elective coronary
angiography for suspected coronary artery disease [21].
doi:10.1371/journal.pone.0029070.g001
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based on retrospective data from CAD/MI-registries, retrospec-
tive selection of premature familial CAD/MI cases and subjects
from several cross sectional studies with angiographically deter-
mined CAD [7–10,13]. The controls used in some of these studies
were recruited from study cohorts with non-cardiovascular disease
such as neurological, psychiatric, infectious disease and cancer or
subjects from population-based studies or healthy blood donors.
Only few studies used angiographically determined controls
without CAD for some of their replications [7,8].
The ‘ideal’ control would be a .90 years old individual with no
prior history of CAD and completely normal coronary arteries.
4
However, this design appears unrealistic and would not permit the
collection of sufficiently large cohorts needed for detection of small
effects or even gene-interactions. Therefore, Luo et al. presented
apparently less stringent criteria for phenotype categorization [3]:
Controls should be characterized by normal coronary arteries by
conventional coronary angiography or multidetector computer
tomography (CT), no family history of CAD, no history of
cerebrovascular or peripheral artery disease and age of controls
much greater than cases (10–20 years). In contrast, cases for
coronary artery disease and myocardial infarction, respectively,
should present with at least one angiographic stenosis $70% in a
major epicardial artery, family history of CAD, no history of
smoking, no diabetes, normal or low LDL-cholesterol, high HDL-
cholesterol and normal C reactive protein. However, today no
study exists that meets these criteria. From the total of 2274
subjects included in the untreated and unaffected cohort 1, only
1.5% and 8.5% fulfilled the complete set of criteria suggested by
Luo et al for CAD cases and controls, respectively. A recent study
has investigated the impact of heterogeneity of phenotype
definition of CAD on genetic association studies [14]. Remark-
ably, these investigators found that differences in phenotype
definition make only a small contribution to between study
heterogeneity. As a limitation, these results were mostly based on
studies of candidate genes, which did not play a role in recent
genome-wide association studies of CAD. The authors conclude
that even though utility of a clear phenotype definition of CAD
might be limited for primary analyses, it might be helpful for
secondary analyses after an association with CAD has been
established [14].
The mode of recruitment of including only subjects referred to
coronary angiography for suspected CAD in cohort 1 is unique to
the Leipzig (LIFE) Heart Study and has the advantage of
simultaneous collection of cases and controls under equal
conditions. Other large angiographic studies have broader
Table 3. Characteristics of male subjects.
Cohort 1 - ‘suspected CAD’ Cohort 2 - ‘myocardial infarction’ Cohort 3 - ‘LMCAD’
Significance Significance Significance
Parameter Men No CAD CAD,50% CAD$50%
No CAD vs.
CAD$50% Men vs. CAD$50% Men vs CAD$50%
n 1457
a 405 (28) 311 (22) 680 (47 ) 438 242
Age (years) 61.0611.2 57.6611.4 63.3610.6 63.5610.6 ,0.001 59.4612.2 ,0.001 68.669.5 ,0.001
BMI 29.664.7 29.864.9 29.965.3 29.464.2 ns 28.664.2 ,0.001 28.364.1 0.002
Diabetes 431 (30) 87 (21) 119 (38) 216 (32) ,0.001 88 (20) ,0.001 105 (43) ,0.001
Smoker (former/
current)
756/298
(52/21)
220/71
(54/18)
170/63
(54/20)
350/149
(52/22)
ns 127/215 (29/49) ,0.001 154/30 (63/
12)
,0.001
Family history 415 (29) 102 (25) 76 (25) 219 (32) 0.047 153 (35) ns 80 (33) ns
SBP/DBP (mmHg) 139/84 137/86 141/84 140/83 0.043/0.001
Gensini score 20.1629.4 0.0 2.762.7 39.9631.7 ,0.001 44.4629.6
Total-C 5.6061.17 5.5061.10 5.5361.08 5.6761.24 0.013 5.1161.08 0.001 4.4461.04 ,0.001
HDL-C 1.1860.34 1.2360.35 1.1860.37 1.1660.33 0.008 1.1760.32 ns 1.1260.31 0.046
LDL-C 3.6261.06 3.4560.96 3.5360.97 3.7561.13 ,0.001 3.1060.97 ,0.001 2.5560.83 ,0.001
TG 1.8161.70 1.8462.43 1.7861.46 2.1061.29 ns 1.7461.09 ,0.001 1.8261.25 0.005
hsTroponin T ng/l 13 (0–2650) 11 (0–1780) 11 (0–480) 14 (0–2650) ,0.001 1574 (10–38280) ,0.001 18 (0–4330) ns
Nt-proBNP 17061207 11061496 15761132 22861035 ns 164965006 ,0.001 49764083 ,0.001
hsCRP mg/l 2.4611.3 1.969.0 2.4610.4 2.7612.8 0.013 43661 ,0.001 3.069.3 ns
% ASA 52 41 49 60 ,0.001 12 ,0.001 87 ,0.001
% RAAS blocker 69 62 77 70 0.026 31 ,0.001 93 ,0.001
% Beta blocker 54 51 52 56 ns 19 ,0.001 90 ,0.001
% Ca antagonist 23 17 28 25 0.011 10 ,0.001 28 ns
% Diuretic 37 32 42 37 ns 8 ,0.001 59 ,0.001
% Statin 35 27 36 39 ,0.001 12 ,0.001 82 ,0.001
BMI, body-mass index in kg/m
2; SBP/DBP, systolic and diastolic blood pressure in mmHg; Total-C/HDL-C/LDL-C, cholesterol in mmol/l; hsCRP, high sensitive C-reactive
protein in mg/l; RAAS, renin-angiotensin-aldosterone-system; ASA, acetylsalicylic acid. Values are given as arithmetic mean 6 standard deviation for normally
distributed parameters, geometric mean 6 standard deviation for non normal distributed parameters or as percent of subjects for categorical items. Statistic differences
between no CAD and CAD $50 were calculated using Students t-test/Kruskal-Walis test for scaled items and Chi-square test for categorical items.
a including 61 men
without angiography.
doi:10.1371/journal.pone.0029070.t003
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Cohort 1 - ‘suspected CAD’
Cohort 2 - ‘myocardial
infarction’ Cohort 3 - ‘LMCAD’
Significance Significance Significance
Parameter Women No CAD CAD,50% CAD$50%
No CAD vs.
CAD$50% Women vs. CAD$50% Women vs CAD$50%
n 817
a 407 (50) 145 (18) 226 (28) 152 59
Age (years) 64.3610.8 61.6610.7 67.468.8 66.7611.0 ,0.001 64.8613.2 ns 70.4610.4 ns
BMI 30.265.5 29.865.4 30.965.5 30.365.6 ns 28.764.9 0.010 28.064.7 0.008
Diabetes 239 (29) 89 (22) 54 (37) 88 (39) ,0.001 46 (30) 0.071 32 (54) 0.026
Smoker (former/
current)
134/93
(16/11)
63/36
(15/9)
22/18
(15/12)
43/36
(19/16)
0.043 20/55
(13/36)
,0.001 14/3 (24/5) ns
Family history 296 (36) 133 (33) 69 (48) 80 (36) ns 47 (29) ns 17 (30) ns
SBP/DBP (mmHg) 136/83 135/85 140/84 137/80 ns/,0.001
Gensini score 9.8620.8 0 2.462.6 32.3627.9 ,0.001 41.4624.3 ,0.001
Total-C 5.8761.16 5.7361.04 5.8961.16 6.1261.31 0.013 5.0061.13 0.001 4.8161.19 ,0.001
HDL-C 1.4860.40 1.5460.40 1.4260.37 1.4360.39 0.006 1.1860.34 ,0.001 1.3460.44 ns
LDL-C 3.7161.10 3.5360.97 3.7561.17 3.9961.23 ,0.001 2.9860.91 ,0.001 2.6960.99 ,0.001
TG 1.7660.90 1.6660.87 1.9361.11 1.8160.81 ns 1.7161.11 ns 1.7760.98 ns
Troponin T ng/l 11 (0–1420) 10 (0–50) 11 (0–180) 14 (0–1420) ,0.001 1709 (50–31580),0.001 18 (0–4790) ns
Nt-proBNP 18861405 1476659 1846638 31762410 0.001 173264068 ,0.001 49961441 ns
hsCRP mg/l 2.767.2 2.365.6 2.968.0 3.568.9 ,0.001 44663 ,0.001 3.7624.0 ns
% ASA 53 45 53 68 ,0.001 13 ,0.001 80 ,0.001
% RAAS blocker 68 65 70 74 0.039 63 0.026 97 ,0.001
% Beta blocker 65 62 73 65 ns 38 ,0.001 97 ,0.001
% Ca antagonist 26 19 37 30 0.010 33 ns 38 0.026
% Diuretic 43 37 52 48 0.019 42 ns 62 ,0.001
% Statin 36 27 45 46 ,0.001 25 ,0.001 88 ,0.001
See legend to Table 3.
a including 39 women without angiography.
doi:10.1371/journal.pone.0029070.t004
Figure 2. Case-control based association and within-CAD association at chromosome 9p21
a.
abased on haplotype block consisting of 4
SNPs, myocardial infarction defined as elevated troponin and culprit coronary lesion at time of recruitment (cohort 1 and 2) or recollected myocardial
infarction (cohort 3), stable CAD defined as obstructive CAD, normal troponin level at time of recruitment and no recollected myocardial infarction
(cohort 1 and 3).
doi:10.1371/journal.pone.0029070.g002
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indications for coronary angiography such as valvular disease [15].
Only few studies perform combined examinations of the three
mostly affected regions of atherosclerosis development such as
coronary, carotid and peripheral arteries. These studies use
computed tomography of coronary calcium as a surrogate
parameter for coronary atherosclerosis [16–18]. To our knowl-
edge, the Leipzig (LIFE) Heart Study is currently the only large-
scale cohort providing angiographic assessment of coronary
arteries combined with sonographic evaluation of carotid and
peripheral atherosclerosis. Another important advantage is the
highly standardized preanalytical process of blood sampling prior
to interventional or surgical treatment of coronary stenosis. This
enables valid analytical studies of blood cell gene-expression [19]
as well as profiling of mediators and biomarkers of metabolism,
atherosclerotic wall pathology and myocardial function, yet
unaffected by revascularization procedures and initiation of
intensive pharmacological treatment.
Limitations of selecting ‘controls’ from patients presenting with
angiographically normal coronary arteries might be the presence
of atherosclerotic lesions without affecting arterial lumen and
patients that will develop significant lesions and coronary events in
future. Angiographic luminography is not suitable to detect
outward remodeling of plaques or fatty streak lesions and small
fibroatheroma which often represent vulnerable plaques. In spite
of these limitations, the classification of cases and controls in the
Leipzig (LIFE) Heart Study according to angiographic findings led
to an initial cohort with sufficient power to confirm the
chromosome 9p21 locus for CAD and verifies the ability to
perform genetic association studies. The odds ratios between 1.47
(CI 1.25–1.72) to 1.58 (CI 1.35–1.85) per risk allele of 4 SNPs on
chromosome 9p21 are within the range of previous work such as
the WTCCC CAD cohort (OR 1.47, CI 1.27–1.70) [20] and a
recent meta-analysis (OR 1.21 and 1.35, depending on age) [21],
confirming the high discriminatory power of our approach.
Assuming that the finally available number of subjects will be
.6,000, that number would be adequate for genetic analysis to
detect low to intermediate effects (OR 1.2) for common SNPs
(MAF.20%). For analysis of very low effects (OR,1.2) or less
frequent variants (MAF,10%) pooling with other studies
providing similar phenotypes will be necessary (Table S2). The
Leipzig (LIFE) Heart Study has already been used for such a
strategy [22].
Another advantage is the availability of cohorts with different
entities of CAD. This also allowed analyses within CAD
populations. Interestingly, we found that patients with LMCAD
had a stronger association with chromosome 9p21 than patients
with obstructive CAD without LMCAD.
This finding is supported by studies displaying a higher
heritability of left main and proximal CAD [23,24]. In contrast,
comparing subjects with stable obstructive CAD to subjects with
myocardial infarction, no association with 9p21 variants was seen.
Table 5. Case-control based association of chromosome 9p21 with CAD.
Objective Myocardial infarction LMCAD All CAD
Control no CAD (812) no CAD (812) no CAD (812)
Case Myocardial infarction (841) LMCAD (492) Obstructive CAD (1797)
Variant OR (95% CI) p OR (95% CI) p OR (95% CI) p
rs10757274 1.53 (1.32–1.77) 1.2610
28 1.74 (1.42–2.14) 1.4610
27 1.56 (1.33–1.83) 3.0610
28
rs2383206 1.53 (1.32–1.78) 2.2610
28 1.76 (1.43–2.17) 1.2610
27 1.58 (1.35–1.85) 1.2610
28
rs2383207 1.51 (1.30–1.75) 5.5610
28 1.69 (1.38–2.08) 5.7610
27 1.53 (1.31–1.79) 1.3610
27
rs10757278 1.46 (1.26–1.69) 5.2610
27 1.65 (1.34–2.04) 2.1610
26 1.47 (1.25–1.72) 2.2610
26
GGGG haploblock 1.54 (1.32–1.80) 7.1610
28 1.74 (1.40–2.16) 6.9610
27 1.55 (1.31–1.84) 2.8610
27
Ordinary logistic regression in an additive model was calculated for combined subsets of CAD adjusted to major risk factors of atherosclerosis (age, gender, smoking,
diabetes, HDL-C- and LDL-C-levels adjusted for statin treatment). Analyses of myocardial infarction were only adjusted for age, gender, smoking, diabetes, but not for
HDL-C and LDL-C, because the latter parameters significantly change during the acute event. ORs are given per allele.
doi:10.1371/journal.pone.0029070.t005
Table 6. Within CAD association of chromosome 9p21 with subcategories of CAD.
Objective Myocardial infarction LMCAD Multi-vessel disease
Control Stable CAD$50% (956) CAD$50% without LMCAD (1305) Single-vessel disease (635)
Case Myocardial infarction (841) LMCAD (492) Multi-vessel disease (1162)
Variant OR (95% CI) p OR (95% CI) p OR (95% CI) p
rs10757274 1.01 (0.88–1.15) 0.94 1.24 (1.03–1.49) 0.020 1.12 (0.92–1.34) 0.278
rs2383206 0.99 (0.86–1.13) 0.87 1.21 (1.01–1.46) 0.039 1.12 (0.98–1.46) 0.074
rs2383207 1.01 (0.88–1.16) 0.89 1.20 (1.01–1.44) 0.044 1.20 (0.98–1.46) 0.074
rs10757278 1.01 (0.88–1.16) 0.87 1.24 (1.03–1.48) 0.022 1.20 (0.99–1.47) 0.069
GGGG haploblock 1.00 (0.87–1.15) 0.98 1.22 (1.01–1.48) 0.042 1.19 (0.97–1.47) 0.097
See legend to Table 5.
doi:10.1371/journal.pone.0029070.t006
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9p21 did not associate with myocardial infarction once stratified
for disease severity [25]. Even though these results show the
general suitability of the study for analyses of CAD subtypes, larger
sample sizes will be needed to obtain more robust results.
In conclusion, the design and recruitment mode of the Leipzig
(LIFE) Heart Study provides a promising basis for innovative
molecular and diagnostic studies in patients with coronary artery
disease. The identification of new potential targets for lifestyle and
pharmacological interventions may lead to an improvement of
prevention, diagnosis and treatment of atherosclerotic diseases.
Supporting Information
Figure S1 Standardized echocardiographic examina-
tion. PLAX – parasternal long axis; PSAX – parasternal short
axis; ALAX – apical long axis; 2,- 3CV – 2-, 3-chamber view,
RVOT – right ventricular outflow tract; LVOT – left ventricular
outflow tract, TVI – tissue velocity imaging, spectral TDI –
spectral tissue doppler imaging; AV – aortic valve; MV – mitral
valve; PV – pulmonary valve; TV – tricuspidal valve.
(TIF)
Figure S2 Standardized sonographic examination of
carotid arteries. CCA – common carotid artery, ICA –
internal carotid artery, ECA – external carotid artery, BFI – B-
flow imaging.
(TIF)
Figure S3 Categorization in no CAD, CAD,50% and
CAD$50% according to visuell estimation of lumen
narrowing illustrated by proximal and medial segments
of the right coronary artery in left-anterior (LAO) and
right-anterior (RAO) projections.
(TIF)
Figure S4 Schematic of the left main trunk (A). Luminal
reduction $50% in the area shaded in red was defined as
LMCAD. Representative images showing angiographically nor-
mal (B) and a obstructed (C) left main trunks.
(TIF)
Figure S5 Chromosome 9p21 tagging SNPs (rs10757274,
rs2383206, rs2383297, rs10757278) – region (left) and
correlation (R
2) in the Leipzig (LIFE) Heart Study (right).
Modified from Holdt et al. [7].
(TIF)
Table S1 Echocardiographic measurements and calcu-
lations.
(DOCX)
Table S2 Sample size calculation for genetic association
studies.
(DOCX)
Data S1 Supporting information with a detailed de-
scription of methods.
(DOCX)
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